利伐沙班预防隐匿性脑梗死与认知下降:COMPASS MRI亚组研究
COMPASS MRI亚组在1445例稳定血管病患者中比较利伐沙班+阿司匹林与阿司匹林对隐匿性脑梗死、微出血和认知的影响,平均随访2.0年。隐匿性脑梗死未显著减少(OR 0.77),但隐匿性脑梗死或缺血性卒中复合终点估计值与总体试验一致(OR 0.53),微出血和认知无影响。
要点
- 利伐沙班+阿司匹林未显著减少隐匿性脑梗死(2.7% vs 3.5%,OR 0.77)。
- 隐匿性脑梗死或缺血性卒中复合终点OR 0.53,与总体试验一致。
- 微出血和认知测试未见治疗效应。
核心结论
- 利伐沙班+阿司匹林未显著减少隐匿性脑梗死,但隐匿性脑梗死或缺血性卒中复合终点的估计值与总体试验对缺血性卒中的效应一致。
研究设计与样本
- COMPASS MRI亚组纳入1445例稳定血管病患者,平均随访2.0年,比较利伐沙班+阿司匹林与阿司匹林。
- 基线和随访完成头颅MRI,由盲法培训读片者集中判读,并系列评估认知和功能。
主要发现
- 基线时493例(34.1%)存在梗死,随访中新发隐匿性脑梗死55例(3.8%)。
- 利伐沙班+阿司匹林组隐匿性脑梗死发生率为2.7%,阿司匹林组为3.5%(OR 0.77,95%CI 0.37-1.60)。
- 隐匿性脑梗死或缺血性卒中复合终点发生率为2.9% vs 5.3%(OR 0.53,95%CI 0.27-1.03)。
- 新发微出血发生于6.6%的参与者,65.7%的参与者白质高信号体积增加,两者均无治疗效应。
- 认知测试未见治疗效应。
临床怎么用
- 对于稳定血管病患者,利伐沙班+阿司匹林虽未显著减少隐匿性脑梗死,但复合终点估计值与总体试验的缺血性卒中获益一致,支持其用于缺血性卒中预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Covert brain infarcts are associated with cognitive decline. It is not known whether therapies that prevent symptomatic stroke prevent covert infarcts. COMPASS compared rivaroxaban with and without aspirin with aspirin for the prevention of stroke, myocardial infarction, and vascular death in participants with stable vascular disease and was terminated early because of benefits of rivaroxaban 2.5 mg twice daily plus aspirin over aspirin. We obtained serial magnetic resonance imagings and cognitive tests in a consenting subgroup of COMPASS patients to examine treatment effects on infarcts, cerebral microbleeds, and white matter hyperintensities. METHODS: Baseline and follow-up magnetic resonance imagings were completed in 1445 participants with a mean (SD) interval of 2.0 (0.7) years. Whole-brain T1, T2 fluid-attenuated inversion recovery, T2* sequences were centrally interpreted by blinded, trained readers. Participants had serial measurements of cognition and function. The primary end point was the proportion of participants with incident covert infarcts. Secondary end points were the composite of clinical stroke and covert brain infarcts, cerebral microbleeds, and white matter hyperintensities. RESULTS: At baseline, 493 (34.1%) participants had infarcts. Incident covert infarcts occurred in 55 (3.8%) participants. In the overall trial rivaroxaban plus aspirin reduced ischemic stroke by 49% (0.7% versus 1.4%; hazard ratio [95% CI], 0.51 [0.38-0.68]). In the magnetic resonance imaging substudy the effects of rivaroxaban+aspirin versus aspirin were: covert infarcts: 2.7% versus 3.5% (odds ratio [95% CI], 0.77 [0.37-1.60]); Covert infarcts or ischemic stroke: 2.9% versus 5.3% (odds ratio [95% CI], 0.53 [0.27-1.03]). Incident microbleeds occurred in 6.6% of participants and 65.7% of participants had an increase in white matter hyperintensities volume with no effect of treatment for either end point. There was no effect on cognitive tests. CONCLUSIONS: Covert infarcts were not significantly reduced by treatment with rivaroxaban and aspirin but estimates for the combination of ischemic stroke and covert infarcts were consistent with the effect on ischemic stroke in the overall trial. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01776424.
引用
- Sharma M, Hart RG, Smith EE, et al. Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. Stroke. 2020. PMID: 32951537. doi:10.1161/STROKEAHA.120.029762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。